Psychedelics
October 1, 2026
Christina Chwyl, Kim Hoffman, Jason B. Luoma et al.
Background Real-world psilocybin use outpaces evidence-based guidance and accessible professional support; understanding psilocybin safety strategy and resource utilization is important for informing education and dissemination initiatives. Methods This qualitative study explored the perspectives of Oregon residents ( N = 31) who plan to/have used psilocybin, employing thematic analysis of...
JAMA Network Open
October 1, 2026
Kim Madden, Breanne Flood, Imad Kashir et al.
Psilocybin has received increased attention as a potential therapeutic intervention, but it is unclear whether news media reporting reflects the strengths and limitations of the clinical trial evidence. To describe the annual counts of published clinical trials of therapeutic psilocybin and contemporaneous media articles and compare tone, efficacy, and safety messaging. This systematic review...
Brain and Behavior
October 2026
Ruiqi Rachel Luo, David J. Berlowitz, Alexander Bryson et al.
Psilocybin is a naturally occurring classic psychedelic associated with widespread changes in brain function and promising therapeutic outcomes in several neuropsychiatric disorders. Complementing these findings, qualitative studies following psilocybin administration have revealed diverse and highly individual effects across multiple domains of subjective experience. However, little is known...
Psychedelics
October 1, 2026
Lorenzo Miller, Cordelia Kuiper Rauch, Keren Chen et al.
Background Psilocybin-assisted therapy has shown robust antidepressant effects among individuals with major depressive disorder (MDD); however, mechanisms of the treatment remain unclear. Depression has been associated with diminished feelings of connectedness to oneself, others, and the world, and psilocybin is thought to facilitate connectedness. This analysis of an open-label trial of...
Journal of Affective Disorders Reports
October 1, 2026
Kevin Byrne, Madeleine Odette, Eric L Garland et al.
ABSTRACT Background Healthcare workers experienced amplified depression and burnout during COVID-19. Both Mindfulness Based Stress Reduction (MBSR) and psilocybin have been shown to reduce depressive symptoms in this population, however the psychological mechanisms by which adding psilocybin to mindfulness training improves depression and trait mindfulness remain incompletely characterized....
Drug Science Policy and Law
October 1, 2026
Gabriel Bélanger, Sue-Ling Chang, Marianne Masse-Grenier et al.
Psilocybin remains prohibited in most jurisdictions, but Switzerland, Canada, and Australia have established tightly regulated clinical access pathways. In this developing landscape, prescribers are pivotal to safe access and must navigate conflicting guidance, uncertainty, and legal risk. Clarifying how current regulations define prescribers’ roles is therefore important for understanding how...
Psychedelics
October 1, 2026
Diego Borbón
In April 2025, New Mexico enacted the Medical Psilocybin Act, establishing the first legislated statewide medical psilocybin program and becoming the third state to authorize supervised psilocybin use. The Act directs the New Mexico Department of Health to build a regulated system where licensed clinicians provide psilocybin to qualified patients in approved settings for treatment-resistant...
Psychology Archives
September 30, 2026
Hüseyin Beyköylü, Merijn Mestdagh, Fred Hasselman et al.
Derived results from an observational study of fourteen adults attending legal psilocybin truffle retreats in the Netherlands. Includes the per-participant time series of the collective variable, dynamic complexity and detected levels; the per-participant summary table; item diagnostics and collective variable validation; the timing of destabilization; two sensitivity analyses; the full...
Frontiers in Pharmacology
September 30, 2026
Kacper Żełabowski, Tomasz Wieczorek, Adam Hamed
Stroboscopic light stimulation (SLS) and psilocybin each induce altered states whose phenomenology and neurophysiology partly overlap, including posterior alpha-band changes and visual imagery. The two states engage the alpha band through different operations - pharmacological suppression under psilocybin and frequency-selective visual drive under SLS. We formalize their possible interaction...
JAMA Network Open
September 29, 2026
Otto Simonsson, Melissa Bradley, Joshua Curtis Black et al.
This cross-sectional study describes health outcomes attributed to recent use of psilocybin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), ibogaine, and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a nationally representative survey of US adults.
International Journal of Innovative Technologies in Social Science
September 28, 2026
Klaudia Karolina Wójcik, Michal Kieres, Krzysztof Sebastian Habirek et al.
The article aims to compare receptor mechanisms related to neurotransmitters for some of the most widely used psychoactive substances - amphetamine, cocaine, ecstasy (MDMA), and psilocybin - and to link these mechanisms to cardiovascular effects, thermoregulation, and neurotoxicity. The review is based mainly on in vitro studies on transporters and receptors, animal models, and controlled...
Zenodo (CERN European Organization for Nuclear Research)
September 27, 2026
Andrea Vittorini
preprint
This hypothesis and perspective article proposes that dosing schedule should be treated as an independent pharmacological variable in psilocybin microdosing research. Existing controlled studies relevant to depression and mood have predominantly used intermittent schedules. The first dedicated randomized trial in major depressive disorder used 2 mg psilocybin once weekly and did not demonstrate...
medRxiv
September 23, 2026
Dominika Dojčánová, Filip Tylš, Marek Nikolič et al.
preprint
Music is a central component of psychedelic settings, yet little experimental work has examined how psilocybin and musical composition influence music-evoked emotional responses in healthy volunteers. This exploratory, double-blind, placebo-controlled study assessed these effects during the plateau phase of psilocybin and the corresponding time window in placebo sessions following oral...
Frontiers in Pharmacology
September 22, 2026
David Ernst Hogg, Jennifer Romanos, Jamie Albiez et al.
There is considerable interest in the concept that psychedelic compounds might facilitate reorganization of emotional processing with therapeutic benefit; in particular, amelioration of excessive focus on past, current and potential-future aversive events, a dominant emotional-cognitive state in stress-related affective disorders. Translational animal models can advance understanding of...
BMJ Open
September 22, 2026
Anna Kristina Eigenbrodt, Poul P Laigaard, Melika Hassani et al.
Recovery of consciousness after brain injury remains a major challenge in the intensive care unit (ICU), and pharmacological treatments that directly promote awakening from coma and other disorders of consciousness (DoC) are lacking. We hypothesise that simultaneously targeting the two core components of consciousness by pharmacological means-arousal with apomorphine and awareness with...
International Journal of Innovative Technologies in Social Science
September 21, 2026
Mateusz Gawin, Emilia Koziara, Mateusz Gadzina et al.
Major depressive disorder (MDD) is one of the leading causes of disability worldwide. A substantial proportion of patients fail to achieve remission through standard monoaminergic therapies, meeting the clinical criteria for treatment-resistant depression (TRD). TRD is associated with significant clinical morbidity and a profound economic burden on healthcare systems. This review evaluates the...
British Journal of Clinical Pharmacology
September 21, 2026
Anna Signor, Stefano Comai, Gianfranco Pasut et al.
AIMS: This study aimed to evaluate the safety, tolerability and pharmacokinetics of a novel oral modified-release psilocybin formulation (REL-P11) in normal-weight and overweight/obese healthy adults and to assess its suitability for controlled, subperceptual exposure, in light of emerging evidence supporting serotonergic modulation in metabolic disorders. METHODS: Simulation-based modelling...
Pharmaceuticals
September 21, 2026
Naama Levy‐Cooperman, Edward M. Sellers, Paul Glue et al.
Background/Objectives: Psilocybin shows therapeutic promise for several psychiatric disorders, but the acute perceptual and cognitive alterations produced by conventional doses (10–25 mg) require in-clinic supervision, which limits scalability. Whether the therapeutically relevant pharmacology of psilocybin can be safely separated from its hallucinogenic activity remains unresolved. To address...
Mini-Reviews in Medicinal Chemistry
September 18, 2026
Fatemeh Abolhasani, Hojjat Rezaiezadeh, Mohammad Amin Langarizadeh et al.
Psilocybin, a compound found in certain species of Psilocybe mushrooms, shows potential as a treatment for various psychiatric conditions. In the past decade, a growing body of evidence has shown the effectiveness of psilocybin in treating conditions, such as treatment-resistant depression, generalized anxiety disorder, post-traumatic stress disorder, and substance use disorders. This review...
Journal of Pain and Symptom Management
September 18, 2026
Megan Miller, Molly Meyers, Candace Oglesby-Adepoju et al.
Psilocybin-assisted therapy (PAT) shows promise for alleviating psychological and existential distress among people with cancer; however, research is limited by homogeneous samples, raising concerns about generalizability and equity. To explore perceptions and attitudes of PAT among a subset of people with cancer who have been underrepresented in research. A qualitative descriptive study was...